Cetera Advisors LLC increased its position in Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 10.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,500 shares of the company’s stock after acquiring an additional 5,500 shares during the period. Cetera Advisors LLC’s holdings in Senseonics were worth $133,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Raymond James Trust N.A. grew its holdings in shares of Senseonics by 11.4% in the 4th quarter. Raymond James Trust N.A. now owns 49,000 shares of the company’s stock worth $127,000 after acquiring an additional 5,000 shares during the period. Cerity Partners LLC grew its holdings in Senseonics by 33.3% during the 4th quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock valued at $52,000 after buying an additional 5,000 shares during the last quarter. Amalgamated Bank acquired a new stake in Senseonics during the 4th quarter valued at $28,000. Principal Financial Group Inc. grew its holdings in Senseonics by 78.0% during the 4th quarter. Principal Financial Group Inc. now owns 25,259 shares of the company’s stock valued at $65,000 after buying an additional 11,071 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Senseonics by 25.0% during the 4th quarter. New York State Common Retirement Fund now owns 65,500 shares of the company’s stock valued at $170,000 after buying an additional 13,100 shares during the last quarter. Institutional investors and hedge funds own 30.66% of the company’s stock.

SENS has been the topic of a number of analyst reports. Piper Jaffray Companies initiated coverage on Senseonics in a report on Tuesday, January 29th. They set a “neutral” rating on the stock. Zacks Investment Research cut Senseonics from a “hold” rating to a “sell” rating in a report on Wednesday, January 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.25.

Shares of Senseonics stock opened at $2.03 on Friday. Senseonics Holdings Inc has a fifty-two week low of $1.93 and a fifty-two week high of $5.29.

Senseonics (NYSEAMERICAN:SENS) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). The business had revenue of $3.42 million during the quarter, compared to the consensus estimate of $4.05 million.

WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://theolympiareport.com/2019/05/24/cetera-advisors-llc-grows-position-in-senseonics-holdings-inc-sens.html.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Want to see what other hedge funds are holding SENS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Senseonics Holdings Inc (NYSEAMERICAN:SENS).

Institutional Ownership by Quarter for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.